Fig. 1.

Information on the malignancy grade of specimens and the expression of SLC46A1. (A) The expression level of SLC46A1 expressions from immunostained specimens. The intracellular SLC46A1 immunostaining was assessed using a semiquantitative scale (0: not detected; 1: weak; 2: moderate; 3: strong). Nuclei positive for MIB-1 were determined by counting at least 1,000 tumor cells. (B) 24 cases of clinical indications and SLC46A1 expression according to the upper images. The malignancy grade was based on the 2007 WHO classification of tumors of the central nervous system. GBM: glioblastoma; GBMO: glioblastoma with oligodendroglial component; AA: anaplastic astrocytoma; AOD: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; OD: oligodendroglioma; OA: oligoastrocytoma; PXA: pleomorphic xanthoastrocytoma; lt: left; rt: right; F: frontal lobe; T: temporal lobe; P: parietal lobe; O: occipital lobe; lat. vent.: lateral ventricle.